Zydus Lifesciences Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Million)
Zydus Lifesciences Ltd · Outcome · 04 Nov 2026, 5:49 pm
Zydus Lifesciences Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Million) ■ Revenue: 79,096 (+29.2% YoY | -1.3% QoQ) ■ EBITDA: 18,945 (-6.0% YoY | -1.8% QoQ) ■ EBITDA Margin (%): 24.0 (-897 bps YoY | -11 bps QoQ) ■ PAT: 9,255 (-26.6% YoY | -3.6% QoQ) ■ EPS (INR): 9.28 (-25.9% YoY | -2.9% QoQ) Zydus Lifesciences Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Million) Segmental Performance Pharmaceuticals ■ Revenue: 65,582 (+23.2% YoY | +4.1% QoQ) ■ EBIT: 13,186 (-25.7% YoY | +5.9% QoQ) ■ EBIT Margin (%): 20.1 (-1325 bps YoY | +34 bps QoQ) Consumer products ■ Revenue: 11,257 (+73.5% YoY | -21.6% QoQ) ■ EBIT: 71.0 (Loss to Profit YoY | -95.6% QoQ) ■ EBIT Margin (%): 0.6 (Loss to Profit YoY | -1060 bps QoQ) Medical technologies ■ Revenue: 2,257 (+47.3% YoY | -20.2% QoQ) ■ EBIT: -928 (-169.0% YoY | -62.8% QoQ) ■ EBIT Margin (%): -41.1 (-1860 bps YoY | -2098 bps QoQ)
Original exchange filing (PDF)
More announcements from Zydus Lifesciences Ltd
- Press Release · 14 Nov 2026
- Completion of transaction · 12 Nov 2026
- Transcript of the post results earnings call held on November 4, 2026. · 07 Nov 2026
- Press Release · 07 Nov 2026
- The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Life Insurance Corporation of India · 06 Nov 2026
- Investor Conference · 06 Nov 2026
- Audio recording of the Company's Investor Call · 05 Nov 2026
- Press Release · 04 Nov 2026
